CDKN3 and cardiac hypertrophy: For example, the cell cycle pathway that included inhibitors Cdkn3 and E2f8 was upregulated in Camk2n1−/− LV.26,27 Furthermore, Fabp4/FABP4 were downregulated in Camk2n1−/− LV and have been shown to promote cardiac hypertrophy in mice and regulate AMPK signaling, actin cytoskeleton, and oxidative phosphorylation,28 all of which were associated with Camk2n1 deletion in our study.